Publications

Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al..  2019.  Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al..  2019.  Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH et al..  2019.  Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.. Mol Cancer Res. 17(2):446-456.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH et al..  2019.  Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.. Mol Cancer Res. 17(2):446-456.

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Gerke T, Beltran H, Wang X, Lee G-SMary, Sboner A, R Karnes J, Klein EA, Davicioni E, Yousefi K, Ross AE et al..  2019.  Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.. Cancer Epidemiol Biomarkers Prev. 28(3):584-590.

Gerke T, Beltran H, Wang X, Lee G-SMary, Sboner A, R Karnes J, Klein EA, Davicioni E, Yousefi K, Ross AE et al..  2019.  Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.. Cancer Epidemiol Biomarkers Prev. 28(3):584-590.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al..  2019.  ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Nowak DG, Katsenelson KCohen, Watrud KE, Chen M, Mathew G, D'Andrea VD, Lee MF, Swamynathan MMosur, Casanova-Salas I, Jibilian MC et al..  2019.  The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.. J Cell Biol. 218(6):1943-1957.

Boehm KMichael, Bhinder B, Raja VJoseph, Dephoure N, Elemento O.  2019.  Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.. BMC Bioinformatics. 20(1):7.